Please login to the form below

Not currently logged in
Email:
Password:

Germany's Ventaleon names biotech entrepeneur CEO

Dr Ulrich Dauer joins group from OMEICOS

Ulrich DauerGauting, Germany-based pharma firm Ventaleon has appointed Dr Ulrich Dauer - a biotech executive and entrepreneur - as its chief executive officer at a time when the company enters late-stage clinical development.

Dauer has several years of senior executive management experience serving Activaero - a private German pharma firm now owned by Vectura - as its chief strategy officer and subsequently at Berlin-based OMEICOS Therapeutics where he was chief executive officer.

He said: “I know Ventaleon’s technology very well from my time at Activaero and believe that the novel inhaled antiviral agents that Ventaleon is developing has the potential to help patients suffering from serious infections such as influenza to get better, faster.

“I very much look forward to growing the company and advancing it into the next stages of development.”

Prior to his time at Activaero, Dauer founded 4SC AG, a biopharmaceutical company that focuses on cancer treatments, and served as its CEO for fourteen years.

Jean Luechinger, chairman of Ventaleon’s supervisory board, said: “We are very pleased to have Dauer lead Ventaleon.

“He is joining the company at a critical time as it advances into late-stage clinical development.

“With many years of effectively leading biotechs, forming strong collaborations with the pharmaceutical industry and successfully completing major financial transactions, Dauer has the ideal skill set to take Ventaleon to the next stage of growth.”

Dauer succeeds Gerhard Scheuch who will continue to serve as a member of the supervisory board of Ventaleon.

5th June 2017

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Bedrock Group

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics